Welcome to the Provis Infusion Clinic
The Provis Infusion Clinic is committed to the delivery of patient-focused services to assist physicians in the management of their patients.
At Provis Infusion Clinic we provide chemotherapy and other infusion services for treatments that are currently not covered under Ontario’s provincial health insurance plan thereby allowing physicians and their patients increased access to certain medications.
Our individualized service is delivered by highly trained professional staff in a non-institutional, friendly environment while operating under the highest standards and observing the Canada Health Act.
Patient safety is paramount to our service offering – we operate in a similar manner to a hospital chemotherapy unit. All infusions are performed by highly skilled oncology nurses, supervised by an on-site physician. All medication are compounded on-site, by pharmacy technicians, under a bio-hazard hood, supervised by oncology pharmacists.
Provis Infusion Clinic is a private Canadian corporation, not affiliated with any other organization or institution.
We look forward to being of service to you.
Graham Vincent, President
The Provis Infusion Clinic
Welcome to the new Provis WebsiteWe are pleased to offer this new website for your information and use. Please copy or click www.provisinfusion.com and update your web browser. .
Why Choose Provis?
- Infusion Services Since 2005
- Over 7000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
The Ride to Conquer CancerThe Provis Pelotons Cycling Team will be participating in the Ride to Conquer Cancer - June 13th and 14th, 2015. The ride is over 220km's from Toronto to Niagara Falls. To date the team has raised close to $6,000 for cancer research. Go Graham, Deb, Steve, Samantha and Dave.
Update – Patient Support Programs
Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®, Treanda® and Kadcyla® Patients: Provis participates in the Roche Patient Assistance Program, Treanda Support Program and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Treanda® and Kadcyla® Read More >>
ASCO News – Early use of docetaxel with hormone therapy prolongs survival in prostate cancer trialStudy results presented at the ASCO annual meeting suggest that adding docetaxel to standard hormone therapy as part of first-line treatment for men with newly diagnosed, advanced hormone-sensitive prostate cancer can extend survival, compared with chemotherapy alone. Lead author Christopher Sweeney noted "this is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic prostate cancer," adding that "the benefit is substantial and warrants this being a new standard treatment." http://www.firstwordpharma.com/node/1214202#axzz33a0EwLJQ
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.
New Combined-Therapy Option For Metastatic Pancreatic CancerCombined Abraxane (nab-paclitaxel) plus gemcitabine provides superior efficacy vs. gemcitabine alone for metastatic pancreatic cancer
Adcetris® Receives Funding from Cancer Care OntarioAdcetris® (Brentuximab) has been funded by CCO for use in patients with Hodgkin's lymphoma who have relapsed disease following autologous stem cell transplant.
Kadcyla® is now offered at the Provis Infusion ClinicKadcyla® is a single agent for the treatment of people with HER2-positive metastatic breast cancer (mBC) who received both prior treatment with HERCEPTIN® (trastuzumab) and a taxane, separately or in combination.